[{"id":"6ed2a0a8-e285-495a-88fa-47a7c1d6b11a","acronym":"KeyPemls-004","url":"https://clinicaltrials.gov/study/NCT05599789","created_at":"2022-10-31T13:56:54.671Z","updated_at":"2025-02-25T14:17:21.972Z","phase":"Phase 2","brief_title":"Pembrolizumab in Combination with Plinabulin and Docetaxel for Metastatic NSCLC After ICIs (KeyPemls-004)","source_id_and_acronym":"NCT05599789 - KeyPemls-004","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • plinabulin (BPI 2358)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 01/21/2025","primary_completion_date":" 01/21/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-18"},{"id":"315448b4-954b-438d-9f7e-ebc2ba97061f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04902040","created_at":"2021-05-26T16:53:16.095Z","updated_at":"2024-07-02T16:35:19.388Z","phase":"Phase 1/2","brief_title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","source_id_and_acronym":"NCT04902040","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-14"},{"id":"82c12a95-3544-4b96-aa4a-050f89916311","acronym":"","url":"https://clinicaltrials.gov/study/NCT05130827","created_at":"2021-11-23T13:53:28.519Z","updated_at":"2024-07-02T16:35:41.054Z","phase":"Phase 2","brief_title":"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)","source_id_and_acronym":"NCT05130827","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plinabulin (BPI 2358) • Neulasta (pegfilgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-08-03"},{"id":"8d66f651-4e59-49f2-8983-465074938b6c","acronym":"DUBLIN-3","url":"https://clinicaltrials.gov/study/NCT02504489","created_at":"2021-01-18T12:05:24.588Z","updated_at":"2024-07-02T16:36:04.183Z","phase":"Phase 3","brief_title":"Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC","source_id_and_acronym":"NCT02504489 - DUBLIN-3","lead_sponsor":"BeyondSpring Pharmaceuticals Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR L858R • EGFR exon 19 deletion • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR L858R • EGFR exon 19 deletion • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • dexamethasone • plinabulin (BPI 2358)"],"overall_status":"Completed","enrollment":" Enrollment 559","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 03/23/2021","primary_completion_date":" 03/23/2021","study_txt":" Completion: 05/23/2021","study_completion_date":" 05/23/2021","last_update_posted":"2022-09-10"}]